Venetoclax in combination with bortezomib, dexamethasone and daratumumab for multiple myeloma

Multiple myeloma (MM) is an incurable plasma cell dyscrasia with a five-year overall survival of 49.6% that is estimated to currently affect 118,539 people in the United States.1 Despite recent advances that have improved outcomes, MM patients inevitably become refractory to therapy; and, thus, must rely on a diversity of treatment options for long-term management of their disease.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research